Immuto Scientific raises $8M, partners with Daiichi Sankyo US

I am thrilled to announce several critical milestones for Immuto: an oversubscribed, $8M fundraise, the realization of our target discovery and drug development platform, and an exciting collaboration with our valued colleagues at Daiichi Sankyo US. We're pleased to have this announcement covered by Boston Business Journal (https://lnkd.in/eCewZ-DP) and FirstWord Pharma (https://lnkd.in/eMENUXCz) Stepping into this next chapter for Immuto Scientific is about doing drug discovery differently. Armed with support from our visionary investors, we are leveraging our AI-enabled structural surfaceomics platform to find the hidden conformations of surface proteins that exist only in disease. By targeting these unique structures, we can develop therapies with unmatched precision. Additionally, working alongside our colleagues at Daiichi Sankyo US, we’re building strong momentum for what’s ahead. So proud to be a member of this team and I’m so excited for everyone to see what we do next.

What if targets were defined by structure, not just expression? That’s the door we’re opening: disease-specific conformations that legacy target ID couldn’t detect. At Immuto Scientific, we’re building a next-gen protein-folding AI grounded in high-resolution structural proteomics to infer in-cell conformational states. It powers our structural surfaceomics platform and enables rational design of antibodies against structural, disease-specific epitopes—targets that simply weren’t visible before. We’re now putting that engine to work with Daiichi Sankyo US in a discovery collaboration to identify cancer-specific surface targets and develop antibodies against them. Grateful to our team and investors for making this possible. #AIinBiotech #ProteinFolding #AntibodyDiscovery #DrugDiscovery

We’re proud to share two major announcements. Immuto Scientific closed a new $8M financing round and launched a drug discovery collaboration with Daiichi Sankyo US to identify novel cancer-specific targets and develop new antibody-based therapies. The greatest challenge in drug discovery today is not a lack of modalities — it’s the shortage of truly novel, disease-specific targets. At Immuto Scientific, we are redefining target discovery with our AI-enabled structural surfaceomics platform, revealing cell-surface protein conformations invisible to conventional omics tools. These hidden structures open new therapeutic opportunities with exceptional precision and selectivity. With this new investment and alongside our partners, we’re propelling our internal oncology pipeline toward IND-enabling studies, expanding into immunology and inflammation and advancing our industry leading AI platform- built to unlock unprecedented insights into disease biology and reveal entirely new therapeutic targets. The financing was led by DYDX Capital with participation from new investors Gravity Fund and NVNG Investment Advisors, LLC and existing investors Great Oaks Venture Capital, WARF Ventures, among others. Read the release for more: https://lnkd.in/guKzprnN Learn more at www.immutotherapeutics.com #drugdiscovery #oncology #cancer #structuralsurfaceomics #targetdiscovery #ADCs #biotech #financing

Proud to announce two major milestones for Immuto Scientific! We’ve closed an oversubscribed $8M financing round and launched our first discovery collaboration with Daiichi Sankyo US to uncover novel surface targets in cancer. We’re pleased to welcome new investors DYDX Capital, Gravity Fund, and NVNG Investment Advisors, LLC to the team, and to deepen our partnership with the investors who have supported us from day one, including Great Oaks Venture Capital, Wisconsin Alumni Research Foundation (WARF) Ventures, and others. Over the last few years, our team has been working relentlessly to build cutting-edge platforms with unparalleled capabilities to uncover novel, disease-specific targets that were hiding in plain sight. That vision is now a reality. By revealing the hidden conformations of cell-surface proteins that define disease at a structural level, we’re expanding the target universe and opening doors to therapies with unprecedented precision and selectivity. We are advancing an internal pipeline of programs with first-in-class potential and collaborating with Daiichi Sankyo to expand into new areas. Together, we are illuminating what the field has long overlooked: the structural fingerprint of disease.   Thank you to our investors, our partners, and the Immuto team for making this vision real.

"Immuto Scientific creates and leverages data that no other group in the world has.” - Spencer M. of DYDX Capital Excited for this $8M round... but also the partnership with Daiichi Sankyo US, to discover new drug targets in solid tumors using its proprietary structural surfaceomics platform and to develop antibodies against these targets. In this funding round, Tundra Angels is thrilled to join up with Spencer M. of DYDX Capital, Adam G. of Gravity Fund, and continue the journey with Greg Keenan, Joshua J. Carson, Katie Rice, and Mike Partsch at Wisconsin Alumni Research Foundation (WARF) Ventures, Great Oaks Venture Capital, Brad Bodden Wisconsin Investment Partners, among others. Collectively, we're excited to be part of unlocking the new era of data‑driven drug discovery. 🚀

🚨 Breaking today: €308M lands in European biotech. One of the biggest raises of the year. German biotech Tubulis GmbH has closed a €308 million Series C, led by Venrock, to advance its antibody-drug conjugate (ADC) platform - one of Europe’s biggest biotech financings this year. It's a pretty important turning point... 🎯 Their Mission: Tubulis GmbH is part of a growing wave of biotechs transforming cancer therapy by: ➡️ Building ADCs that target tumours with extreme precision - sparing healthy tissue ➡️ Focusing first on ovarian and lung cancers, where options are limited and toxicity is high ➡️ Engineering platform-scale reliability - the leap from discovery to deliverability 💰 Why This Is Important: This round signals far more than capital inflow: → It shows global investors are backing deep science again, not short-term hype → It validates Europe’s emergence as a serious hub for complex biologics → It highlights a structural shift - oncology’s future will be engineered, not discovered For context: €308M is not common in Europe’s current market. It’s one of those pivot moments that shows where conviction - and capital - are heading next. 🌍 The Implications: 𝐅𝐨𝐫 𝐩𝐚𝐭𝐢𝐞𝐧𝐭𝐬 → a future of more targeted, more tolerable treatment options 𝐅𝐨𝐫 𝐛𝐢𝐨𝐭𝐞𝐜𝐡 → proof that precision manufacturing, not just discovery, will define the next decade 𝐅𝐨𝐫 𝐢𝐧𝐯𝐞𝐬𝐭𝐨𝐫𝐬 → a clear signal that the next growth cycle is being built now, molecule by molecule €308 million..... 𝐂𝐨𝐧𝐯𝐢𝐜𝐭𝐢𝐨𝐧 𝐢𝐬 𝐛𝐚𝐜𝐤. #funding #biotech #ADC #investor #pharmaceuticals #growth

SFBN Feed: A year after collaborating with Gilead, Cartography maps out its own Phase 1 with $67M Series B https://lnkd.in/gGENCBDN Pfizer and Amgen’s corporate venture arms are jumping into T cell engagers by investing in Cartography Biosciences’ $67 million Series B. The Bay Area startup, which is developing bispecific and multispecific antibodies for cancer patients [...] #BayArea #SanFrancisco #Biotech #Lifescience #News

R&D in precision oncology diagnostics isn’t just for early-stage science. At the start, R&D drives discovery, finding new biomarkers, testing assays, proving concepts. But once a product hits the market, the role doesn’t disappear. Commercial-stage R&D keeps the product: 🔬 Performing at its best 📈 Expanding into new indications or partnerships 🤝 Linking science to what clinicians, payors, and partners actually need The best R&D leaders can do both, innovate early and translate that science into long-term commercial impact. 💭 What makes an R&D leader great at both discovery and commercialisation? #PrecisionOncology #Diagnostics #RandD #Leadership #Biotech #Innovation

🚀 At Columbus Venture Partners we are proud to share great news from our portfolio: ARTHEx Biotech has successfully closed an upsized Series B round of $87M. This financing, led by Bpifrance and joined by all existing investors, will accelerate the global clinical development of ATX-01, a first-in-class RNA therapeutic for Myotonic Dystrophy Type 1 (DM1), and expand the company’s pipeline into other diseases with high unmet needs. At #Columbus, we continue to back pioneering science that creates impact for patients and delivers strong value for investors 🧬✨ #Biotech #VentureCapital #RNATherapeutics #DM1 #InvestingInHealth https://lnkd.in/dtxmsYYs

A year after collaborating with Gilead, Cartography maps out its own Phase 1 with $67M Series B https://lnkd.in/gc2eQ8XF Pfizer and Amgen’s corporate venture arms are jumping into T cell engagers by investing in Cartography Biosciences’ $67 million Series B. The Bay Area startup, which is developing bispecific and multispecific antibodies for cancer patients [...] #LosAngeles #OrangeCountyCA #Biotech #Lifescience #News